The data suggests that targeting AKT is an effective strategy in ER+ BC preclinical models with PIK3CA mutations with or without compromised PTEN protein expression due to in part regulation of FOXO3 translocation driving PI3K-AKTi mediated cell cycle arrest in part through FOXM1 inhibition. This evidence concerns the gene FOXO3 and breast cancer.